---
title: Hokusai Study in Pediatric Patients With Confirmed Venous Thromboembolism (VTE)
nct_id: NCT02798471
overall_status: COMPLETED
phase: PHASE3
sponsor: Daiichi Sankyo
study_type: INTERVENTIONAL
primary_condition: Venous Thromboembolism (VTE)
countries: United States, Argentina, Brazil, Bulgaria, Canada, Chile, Croatia, Czechia, Denmark, El Salvador, France, Germany, Guatemala, Hungary, India, Israel, Kenya, Lebanon, Malaysia, Netherlands, Norway, Panama, Portugal, Romania, Russia, Serbia, Singapore, Slovenia, South Korea, Spain, Taiwan, Thailand, Turkey (Türkiye), Ukraine
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT02798471.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT02798471"
ct_last_update_post_date: 2025-02-28
last_seen_at: "2026-05-12T06:34:57.085Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# Hokusai Study in Pediatric Patients With Confirmed Venous Thromboembolism (VTE)

**Official Title:** A Phase 3, Open-label, Randomized, Multi-center, Controlled Trial to Evaluate the Pharmacokinetics and Pharmacodynamics of Edoxaban and to Compare the Efficacy and Safety of Edoxaban With Standard of Care Anticoagulant Therapy in Pediatric Subjects From Birth to Less Than 18 Years of Age With Confirmed Venous Thromboembolism (VTE)

**NCT ID:** [NCT02798471](https://clinicaltrials.gov/study/NCT02798471)

## Key Facts

- **Status:** COMPLETED
- **Phase:** PHASE3
- **Study Type:** INTERVENTIONAL
- **Target Enrollment:** 290
- **Lead Sponsor:** Daiichi Sankyo
- **Conditions:** Venous Thromboembolism (VTE), Pulmonary Embolism, Deep Vein Thrombosis (DVT)
- **Start Date:** 2017-03-27
- **Completion Date:** 2022-05-24
- **CT.gov Last Update:** 2025-02-28

## Brief Summary

This is an event driven Phase 3, prospective, randomized, open-label, blinded endpoint evaluation (PROBE) parallel group study in subjects with confirmed VTE. This study is designed to evaluate the pharmacokinetics (PK) and pharmacodynamics (PD) of edoxaban and to compare the efficacy and safety of edoxaban against standard of care in pediatric subjects with confirmed VTE.

## Detailed Description

The objective is to demonstrate the non-inferiority of edoxaban to standard of care (SOC; including low molecular weight heparin (LMWH), vitamin K antagonist (VKA), or synthetic pentasaccharide (SP) Xa inhibitors) in the treatment and secondary prevention of VTE in pediatric subjects with regard to the composite efficacy endpoint (ie, symptomatic recurrent VTE, death as result of VTE, and no change or extension of thrombotic burden) during the first 3-month treatment period.

## Eligibility

- **Minimum age:** 1 Day
- **Maximum age:** 17 Years
- **Sex:** ALL
- **Healthy Volunteers:** No

```
Inclusion Criteria:

1. Male or female pediatric subjects between birth (defined as 38 weeks gestational age) and less than 18 years of age at the time of consent.
2. Pediatric subjects with the presence of documented VTE confirmed by appropriate diagnostic imaging and requiring anticoagulant therapy for at least 90 days.
3. Subjects must have received at least 5 days of heparin therapy prior to randomization to treat the newly identified index VTE. In addition, prior to being randomized to edoxaban or SOC, subjects initially treated with VKA are recommended to have an international normalized ratio (INR) \< 2.0.
4. Subject and/or parent(s)/legal guardian(s) or legally acceptable representative is informed and provides signed consent for the child to participate in the study.
5. Female subjects who have menarche must test negative for pregnancy at Screening and must consent to avoid becoming pregnant by using an approved contraception method throughout the study.

Exclusion Criteria:

1. Subjects with active bleeding or high risk of bleeding contraindicating treatment with LMWH, SP Xa inhibitors, VKAs, or direct oral anticoagulants (DOACs; identified high risk of bleeding during prior experimental administration of DOACs).
2. Subjects who have been or are being treated with thrombolytic agents, thrombectomy or insertion of a caval filter for the newly identified index VTE.
3. Administration of antiplatelet therapy is contraindicated in both arms except for low dose aspirin defined as 1-5 mg/Kg/day with maximum of 100 mg/day.
4. Administration of rifampin is prohibited during the study and subjects on concomitant use of rifampin are excluded.
5. Subjects with hepatic disease associated with coagulopathy leading to a clinically relevant bleeding risk (aPTT \> 50 seconds or international normalized ratio \[INR\] \> 2.0 not related to anticoagulation therapy) or alanine aminotransferase (ALT) \> 5 × the upper limit of normal (ULN) or total bilirubin \> 2 × ULN with direct bilirubin \> 20% of the total at Screening Visit.
6. Subjects with glomerular filtration rate (GFR) \< 30% of normal for age and size as determined by the Schwartz formula.
7. Subjects with stage 2 hypertension defined as blood pressure (BP) systolic and/or diastolic confirmed \> 99th percentile + 5 mmHg.
8. Subject with thrombocytopenia \< 50 × 109/L at Screening Visit. Subjects with a history of heparin-induced thrombocytopenia may be enrolled in the study at the Investigator's discretion.
9. Life expectancy less than the expected study treatment duration (3 months).
10. Subjects who are known to be pregnant or breastfeeding.
11. Subjects with any condition that, as judged by the Investigator, would place the subject at increased risk of harm if he/she participated in the study, including contraindicated medications.
12. Subjects who participated in another clinical study or treated with an experimental therapy with less than a 30 day washout period prior to identifying the qualifying index VTE.
```

## Arms

- **Edoxaban** (EXPERIMENTAL) — Edoxaban treatment will be dispensed to the participant on a monthly visit schedule.

Edoxaban will be started orally at the age/weight/renal function appropriate dose, depending on the results of the ongoing U157 study (NCT02303431) for the Treatment Period.
- **Standard of Care** (EXPERIMENTAL) — Standard of Care (SOC) treatment will be dispensed to the participant on a monthly visit schedule.

## Interventions

- **Edoxaban** (DRUG) — 15 or 30 mg tablets for participants 12 years of age to \<18, and 60 mg edoxaban suspension for oral administration to participants under 12 years of age
- **Standard of Care** (DRUG) — Standard of care could include low molecular weight heparin (LMWH), vitamin K antagonist (VKA), or synthetic pentasaccharide (SP) Xa inhibitors.

## Primary Outcomes

- **Number of Participants With Symptomatic Recurrent Venous Thromboembolism During the Main Treatment Period Following Edoxaban or Standard of Care Treatment (Adjudicated Composite)** _(time frame: Randomization to Month 3)_ — Diagnosis of recurrent venous thromboembolism (VTE) requires the confirmation by diagnostic imaging and at least one of the symptoms of VTE from such areas as lower or upper extremity, catheter related thrombosis, pulmonary embolism, or sinovenous thrombosis.
- **Number of Participants Who Died as a Result of VTE During the Main Treatment Period Following Edoxaban or Standard of Care Treatment (Adjudicated Composite)** _(time frame: Randomization to Month 3)_ — Death from venous thromboembolism (VTE) is based on objective diagnostic testing, autopsy or death which cannot be attributed to documented cause for which VTE cannot be ruled out.
- **Number of Participants With No Change or Extension of Thrombotic Burden During the Main Treatment Period Following Edoxaban or Standard of Care Treatment (Adjudicated Composite)** _(time frame: Randomization to Month 3)_ — No change or extension of thrombotic burden as assessed by quantitative diagnostic imaging of the index qualifying VTE thrombus at baseline and at Month 3. Imaging criteria for VTE included: - Abnormal compression ultrasonography where compression had been normal or, if non-compressible during screening, an increase in diameter of the thrombus during full compression; - An extension of the echogenic intra-luminal thrombus or absence of flow in the central venous system on Doppler ultrasonography. - An extension of an intraluminal filling defect, or a new intraluminal filling defect, or an extension of non-visualization of veins in the presence of a sudden cut-off on venography. - An extension of an intraluminal filling defect, or a new intraluminal filling defect on computed tomography angiogram (CTA).

## Secondary Outcomes

- **Number of Participants With Symptomatic Recurrent Venous Thromboembolism During the Overall Treatment Period Following Edoxaban or Standard of Care Treatment (Adjudicated Composite)** _(time frame: From randomization up to Month 12)_
- **Number of Participants With Symptomatic Recurrent VTE During the Main Treatment Period Following Edoxaban or Standard of Care Treatment (Adjudicated Individual Component of Primary Efficacy Endpoint)** _(time frame: Randomization to Month 3)_
- **Number of Participants Who Died as a Result of VTE During the Overall Treatment Period Following Edoxaban or Standard of Care Treatment (Adjudicated Composite)** _(time frame: From randomization up to Month 12)_
- **Number of Participants Who Died as a Result of VTE During the Main Treatment Period Following Edoxaban or Standard of Care Treatment (Adjudicated Individual Component of Primary Efficacy Endpoint)** _(time frame: Randomization to Month 3)_
- **Number of Participants With No Change or Extension of Thrombotic Burden During the Overall Treatment Period Following Edoxaban or Standard of Care Treatment (Adjudicated Composite)** _(time frame: From randomization up to Month 12)_
- **Number of Participants With Adjudicated Individual Component of Primary Efficacy Endpoints During the Main Treatment Period Following Edoxaban or Standard of Care Treatment** _(time frame: Randomization to Month 3)_
- **Number of Participants Reporting Adjudicated All-Cause Mortality During the Overall Treatment Period Following Edoxaban or Standard of Care Treatment (Adjudicated)** _(time frame: From randomization up to Month 12)_
- **Number of Participants With Deep Vein Thrombosis, Catheter-related Thrombosis, Sino-venous Thrombosis, and Pulmonary Embolism During the Main, Extension, and Overall Treatment Periods Following Edoxaban or Standard of Care Treatment** _(time frame: From randomization up to Month 12)_
- **Number of Participants With Major and Clinically Relevant Non-Major Bleeding Events (On Treatment) During the Main Treatment Period Following Edoxaban or Standard of Care Treatment (Adjudicated Composite)** _(time frame: Randomization to Month 3)_
- **Number of Participants With All Bleeding Events (On Treatment) During the Overall Treatment Period Following Edoxaban or Standard of Care Treatment (Adjudicated Composite)** _(time frame: From randomization up to Month 12)_
- **Number of Participants With Major and Clinically Relevant Non-Major Bleeding Events (On Treatment) During the Overall Treatment Period Following Edoxaban or Standard of Care Treatment (Adjudicated Composite)** _(time frame: From randomization up to Month 12)_

## Locations (140)

- Banner University Medical Center, Tucson, Arizona, United States
- Children's Hospital Los Angeles, Los Angeles, California, United States
- UCLA Medical Center CAR, Los Angeles, California, United States
- Stanford University Medical Center, Stanford, California, United States
- University of Miami Miller School of Medicine, Miami, Florida, United States
- University of South Florida, Tampa, Florida, United States
- Rush University Medical Center, Chicago, Illinois, United States
- Advocate Children's Hospital-Oak Lawn, Oak Lawn, Illinois, United States
- Indiana Hemophilia and Thrombosis Center, Indianapolis, Indiana, United States
- University of Louisville, Louisville, Kentucky, United States
- Spectrum Health Helen DeVos Children's Hospital Grand Rapids, Grand Rapids, Michigan, United States
- Children's Hospital & Clinics of Minnesota, Minneapolis, Minnesota, United States
- Washington University School of Medicine, St Louis, Missouri, United States
- University North Carolina- Chapel Hill, Chapel Hill, North Carolina, United States
- Levine Children's Hospital Charlotte, Charlotte, North Carolina, United States
- The Presbyterian Hospital, Charlotte, North Carolina, United States
- East Carolina University, Greenville, North Carolina, United States
- University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, United States
- Hasbro Children's Hospital, Providence, Rhode Island, United States
- Le Bonheur Childrens Hospital, Memphis, Tennessee, United States
- St. Jude Children's Research Hospital, Memphis, Tennessee, United States
- Children's Hospital of Wisconsin, Milwaukee, Wisconsin, United States
- Hospital Italiano Regional del Sur, Buenos Aires, Argentina
- Sanatorio Allende, Córdoba, Argentina
- Hospital Erasto Gaertner - Liga Paranaense de Combate ao Câncer, Curitiba, Paraná, Brazil
- IMIP - Instituto de Medicina Integral Professor Fernando Figueira, Pernambuco, Recife, Brazil
- Hospital São Vicente de Paulo, Passo Fundo, Rio Grande do Sul, Brazil
- Hospital da Cidade de Passo Fundo, Passo Fundo, Rio Grande do Sul, Brazil
- Instituto de Cardiologia do Rio Grande do Sul, Pôrto Alegre, Rio Grande do Sul, Brazil
- Hospital de Câncer de Barretos - Fundação Pio XII, Barretos, São Paulo, Brazil
- Centro de Hematologia e Hemoterapia - Hemocentro de Campinas - UNICAMP, Campinas, São Paulo, Brazil
- Centro Multidisciplinar de Estudos Clínicos - CEMEC, Santo André, São Paulo, Brazil
- Santa Casa de Votuporanga, Votuporanga, São Paulo, Brazil
- Hospital Samaritano, São Paulo, Brazil
- Hospital da Luz Amico Saude LTDA, São Paulo, Brazil
- Hospital Infantil Pequeno Príncipe, São Paulo, Brazil
- GRAACC - Grupo de Apoio ao Adolescente e à Criança com Câncer, São Paulo, Brazil
- UNIFESP - Universidade Federal de São Paulo, São Paulo, Brazil
- Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil
- HMCG - Hospital e Maternidade Dr. Christovão da Gama, São Paulo, Brazil
- UMHAT "Sv. Georgi", EAD, Plovdiv, Bulgaria
- MHAT - "National Heart Hospital" EAD, Sofia, Bulgaria
- MHAT 'Tokuda Hospital Sofia', EAD, Sofia, Bulgaria
- Medical Center for Specialized Ambulatory Medical Assistance for Children's Diseases, Sofia, Bulgaria
- Edmonton Clinic Health Academy, Edmonton, Alberta, Canada
- CancerCare Manitoba, Winnipeg, Manitoba, Canada
- McMaster Children's Hospital, Hamilton, Ontario, Canada
- Hospital El Carmen Dr. Luis Valentin Ferrada, Maipú, Chile
- Clinica Las Condes, Santiago, Chile
- Clinical Hospital Centre Rijeka, Rijeka, Croatia
- General Hospital Zadar, Zadar, Croatia
- Children's Hospital Zagreb, Zagreb, Croatia
- University Hospital Centre Zagreb, University of Zagreb School of Medicine, Zagreb, Croatia
- Fakultni nemocnice Brno, Brno, Czechia
- CTC Hodonin s.r.o., Hodonín, Czechia
- Dětská klinika Fakultní nemocnice, Hradec Králové, Czechia
- University Hospital Pilsen, CZ, Pilsen, Czechia
- Ålborg Universitetshospital, Aalborg, Denmark
- Hospital Nacional de Niños Benjamín Bloom, San Salvador, Salvador, El Salvador
- Clinical Hospital Centre Cavale Blanche BREST, Brest, Finistere, France
- Groupe Hospitalier Sud - Hôpital Haut-Lévêque, Pessac, Gironde, France
- Hôpital des enfants, CHU Toulouse, Toulouse, Haute Garonne, France
- CHU Rennes - Hopital Sud, Rennes, Ille Et Vilaine, France
- CHU Angers - Hôpital Hôtel Dieu, Angers, France
- CHU Clermont Ferrand - Hôpital d'Estaing, Clermont-Ferrand, France
- CHU Arnaud de Villeneuve, Montpellier, France
- Universitaetsklinikum Essen, Essen, North Rhine-Westphalia, Germany
- Charite - Campus Virchow-Klinikum, Berlin, Germany
- Unidad de Cirugía Cardiovascular de Guatemala (UNICAR), Guatemala City, Guatemala
- Unidad Nacional de Oncología Pediátrica (UNOP), Guatemala City, Guatemala
- Semmelweis University 2nd Department of Pediatrics, Budapest, Hungary
- Central Hospital of Southern Pest - National Institute of Hematology and Infectious Diseases, Budapest, Hungary
- Debreceni Egyetem Klinikai Kozpont, Debrecen, Hungary
- University of Szeged, Department of Pediatrics, Szeged, Hungary
- Shree Krishna Hospital & Medical Research Centre, H M Patel Centre for Medical Care and Education, Karamsad, Gujarat, India
- Nirmal Hospital, Surat, Gujarat, India
- Jain Institute of Vascular Sciences, Bangalore, Karnataka, India
- M. S. Ramaiah Medical College and Hospital, Bangalore, Karnataka, India
- Government Medical College and Hospital, Nagpur, Maharashtra, India
- Sir Ganga Ram Hospital, New Delhi, National Capital Territory of Delhi, India
- Christian Medical College, Ludhiana, Punjab, India
- Institute of Child Health, Kolkata, West Bengal, India
- Indraprastha Apollo Hospitals, Delhi, India
- Rambam Medical Center, Haifa, Israel
- Shaare Zedek Medical Center, Jerusalem, Israel
- Hadassah ein Kerem, Jerusalem, Israel
- Chaim Sheba Medical Center, Ramat Gan, Israel
- Strathmore University Medical Centre, Nairobi, Kenya
- American University of Beirut Medical Center, Beirut, Lebanon
- Saint George University Hospital Medical Center, Beirut, Lebanon
- Hotel Dieu de France Hospital, Beirut, Lebanon
- Hospital Raja Perempuan Zainab II, Kota Bharu, Kelantan, Malaysia
- Erasmus MC Sophia, Rotterdam, Netherlands
- Oslo University Hospital, Oslo, Norway
- INDICASAT AIP Site 7871, Panama City, Panama
- INDICASAT AIP Site 7872, Panama City, Panama
- Hospital de Braga, Braga, Portugal
- Hospital da Senhora da Oliveira, Guimarães, Portugal
- Centro Hospitalar de Lisboa Central, E.P.E. - Hospital de Santa Marta, Lisbon, Portugal
- Centro Hospitalar de Lisboa Norte, E.P.E. - Hospital de Santa Maria, Lisbon, Portugal
- S.C Centrul Clinic Mediquest S.R.L, Sângeorgiu de Mureş, Romania
- FSBI of Science "Kirov Scientific and Research Institute of Hematology and Blood Transfusion, FMBA", Kirov, Russia
- Russian Scientific Center of Radiology and Nuclear Medicine of Ministry of Health of Russian Federation, Department of Pediatric Oncology, Moscow, Russia
- Mother and Child Health Care Institute of Serbia "Dr. Vukan Cupic", Belgrade, Serbia
- Clinical Center Kragujevac, Kragujevac, Serbia
- National University Hospital, Singapore, Singapore
- KK Women's And Children's Hospital, Singapore, Singapore
- University Medical Centre Ljubljana, Ljubljana, Slovenia
- Seoul National University Bundang Hospital, Seongnam-si, Gyeonggi-do, South Korea
- Seoul National University Hospital, Seoul, South Korea
- Severance Hospital, Yonsei University, Seoul, South Korea
- Samsung Medical Center, Seoul, South Korea
- Hospital Universitari Vall d'Hebron, Barcelona, Spain
- Hospital Universitario La Paz, Madrid, Spain
- Hospital Universitario Virgen Macarena, Seville, Spain
- Hospital Universitario Araba, Vitoria-Gasteiz, Álava, Spain
- Buddhist Tzu Chi General Hospital, Hualien City, Taiwan
- Kaohsiung Veterans General Hospital, Kaohsiung City, Taiwan
- China Medical University Hospital, Taichung, Taiwan
- Taichung Veterans General Hospital, Taichung, Taiwan
- Taipei Medical University Hospital, Taipei, Taiwan
- Ramathibodi Hospital, Bangkok, Thailand
- King Chulalongkorn Memorial Hospital, Bangkok, Thailand
- Phramongkutklao Hospital, Bangkok, Thailand
- Chiang Mai University Hospital, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand
- Srinagarind Hospital, Khon Kaen, Thailand
- Songklanagarind Hospital, Songkhla, Thailand
- Cukurova University Faculty of Medicine Balcali Hospital Pediatry Department, Adana, Turkey (Türkiye)
- Hacettepe University Medical Faculty, Ankara, Turkey (Türkiye)
- Ankara Çocuk Sağlığı Ve Hastalıkları Hematoloji Onkoloji Eğitim Araştırma Hastanesi, Ankara, Turkey (Türkiye)
- Istanbul University Istanbul Medical Faculty, Istanbul, Turkey (Türkiye)
- Yeditepe University Oncology Hospital, Istanbul, Turkey (Türkiye)
- Ege University Medical Faculty, Izmir, Turkey (Türkiye)
- Izmir Tepecik Training and Research Hospital, Izmir, Turkey (Türkiye)
- Izmir Dr. Behcet Uz Cocuk Hastaliklari ve Cerrahisi Egitim ve Arastirma Hastanesi, Izmir, Turkey (Türkiye)
- Erciyes University Medical Faculty, Kayseri, Turkey (Türkiye)
- Mersin University Health Research and Practice Hospital, Mersin, Turkey (Türkiye)
- Regional Children's Clinical Hospital, Dnipro, Ukraine
- CI of Healthcare Regional Children CH Gastroenterology Center Kharkiv NMU, Kharkiv, Ukraine
- Children City Clinical Hospital, Poltava, Ukraine

## Recent Field Changes (last 30 days)

- `status.overallStatus` — added _(2026-05-12)_
- `status.primaryCompletionDate` — added _(2026-05-12)_
- `status.completionDate` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `design.phases` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.minAge` — added _(2026-05-12)_
- `eligibility.maxAge` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `outcomes.primary` — added _(2026-05-12)_
- `outcomes.secondary` — added _(2026-05-12)_
- `armsInterventions.arms` — added _(2026-05-12)_
- `armsInterventions.interventions` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_
- `locations.banner university medical center|tucson|arizona|united states` — added _(2026-05-12)_
- `locations.children's hospital los angeles|los angeles|california|united states` — added _(2026-05-12)_
- `locations.ucla medical center car|los angeles|california|united states` — added _(2026-05-12)_
- `locations.stanford university medical center|stanford|california|united states` — added _(2026-05-12)_
- `locations.university of miami miller school of medicine|miami|florida|united states` — added _(2026-05-12)_
- `locations.university of south florida|tampa|florida|united states` — added _(2026-05-12)_
- `locations.rush university medical center|chicago|illinois|united states` — added _(2026-05-12)_
- `locations.advocate children's hospital-oak lawn|oak lawn|illinois|united states` — added _(2026-05-12)_
- `locations.indiana hemophilia and thrombosis center|indianapolis|indiana|united states` — added _(2026-05-12)_
- `locations.university of louisville|louisville|kentucky|united states` — added _(2026-05-12)_
- `locations.spectrum health helen devos children's hospital grand rapids|grand rapids|michigan|united states` — added _(2026-05-12)_
- `locations.children's hospital & clinics of minnesota|minneapolis|minnesota|united states` — added _(2026-05-12)_
- `locations.washington university school of medicine|st louis|missouri|united states` — added _(2026-05-12)_
- `locations.university north carolina- chapel hill|chapel hill|north carolina|united states` — added _(2026-05-12)_
- `locations.levine children's hospital charlotte|charlotte|north carolina|united states` — added _(2026-05-12)_
- `locations.the presbyterian hospital|charlotte|north carolina|united states` — added _(2026-05-12)_
- `locations.east carolina university|greenville|north carolina|united states` — added _(2026-05-12)_
- `locations.university of oklahoma health sciences center|oklahoma city|oklahoma|united states` — added _(2026-05-12)_
- `locations.hasbro children's hospital|providence|rhode island|united states` — added _(2026-05-12)_
- `locations.le bonheur childrens hospital|memphis|tennessee|united states` — added _(2026-05-12)_
- `locations.st. jude children's research hospital|memphis|tennessee|united states` — added _(2026-05-12)_
- `locations.children's hospital of wisconsin|milwaukee|wisconsin|united states` — added _(2026-05-12)_
- `locations.hospital italiano regional del sur|buenos aires||argentina` — added _(2026-05-12)_
- `locations.sanatorio allende|córdoba||argentina` — added _(2026-05-12)_
- `locations.hospital erasto gaertner - liga paranaense de combate ao câncer|curitiba|paraná|brazil` — added _(2026-05-12)_
- `locations.imip - instituto de medicina integral professor fernando figueira|pernambuco|recife|brazil` — added _(2026-05-12)_
- `locations.hospital são vicente de paulo|passo fundo|rio grande do sul|brazil` — added _(2026-05-12)_
- `locations.hospital infantil pequeno príncipe|são paulo||brazil` — added _(2026-05-12)_
- `locations.hospital da cidade de passo fundo|passo fundo|rio grande do sul|brazil` — added _(2026-05-12)_
- `locations.instituto de cardiologia do rio grande do sul|pôrto alegre|rio grande do sul|brazil` — added _(2026-05-12)_
- `locations.hospital de câncer de barretos - fundação pio xii|barretos|são paulo|brazil` — added _(2026-05-12)_
- `locations.centro de hematologia e hemoterapia - hemocentro de campinas - unicamp|campinas|são paulo|brazil` — added _(2026-05-12)_
- `locations.centro multidisciplinar de estudos clínicos - cemec|santo andré|são paulo|brazil` — added _(2026-05-12)_
- `locations.santa casa de votuporanga|votuporanga|são paulo|brazil` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT02798471.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT02798471*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*